[
  {
    "ts": null,
    "headline": "Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound",
    "summary": "Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more affordable for clinically eligible individuals. The collaboration integrates diagnosis, prescription, and home delivery into one platform. Also Read: Eli Lilly Investments In Production Reach $23 Billion",
    "url": "https://finnhub.io/api/news?id=d9bb68444dd6fc04a33d148aab54a5fb03125e18abb1d7a87ee4f641fe51dee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734014324,
      "headline": "Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound",
      "id": 131931860,
      "image": "https://media.zenfs.com/en/Benzinga/3d6da6d80450b2eb920b70fd84b68dd3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more affordable for clinically eligible individuals. The collaboration integrates diagnosis, prescription, and home delivery into one platform. Also Read: Eli Lilly Investments In Production Reach $23 Billion",
      "url": "https://finnhub.io/api/news?id=d9bb68444dd6fc04a33d148aab54a5fb03125e18abb1d7a87ee4f641fe51dee8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study",
    "summary": "Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.",
    "url": "https://finnhub.io/api/news?id=822dfed8e26e47081c10638b23d6b263b25032cf2d73bfb99b650f0529dce82c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734010740,
      "headline": "Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study",
      "id": 131936528,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.",
      "url": "https://finnhub.io/api/news?id=822dfed8e26e47081c10638b23d6b263b25032cf2d73bfb99b650f0529dce82c"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks to Keep an Eye on After Dividend Hike Announcement",
    "summary": "Stocks like SYK, LLY and AES recently announced dividend hikes.",
    "url": "https://finnhub.io/api/news?id=7591e04b0cc51a58a36353d9313e1ffc1f877cb2f123d59b27c35c80c2da486e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734009840,
      "headline": "3 Stocks to Keep an Eye on After Dividend Hike Announcement",
      "id": 131929230,
      "image": "https://media.zenfs.com/en/zacks.com/72e92f2def8e0975361faddc09fe1438",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks like SYK, LLY and AES recently announced dividend hikes.",
      "url": "https://finnhub.io/api/news?id=7591e04b0cc51a58a36353d9313e1ffc1f877cb2f123d59b27c35c80c2da486e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025",
    "summary": "Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now.  Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.  It's one that investors should keep a close eye on because it could send the stock to record highs in 2025.",
    "url": "https://finnhub.io/api/news?id=2f691d66c1f43051fd84b4d8ab8e495bc31cc423ac0980c5636b516d39835474",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734007500,
      "headline": "Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025",
      "id": 131941683,
      "image": "https://g.foolcdn.com/editorial/images/800295/pharmacist-handing-prescription-medication-to-a-customer.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now.  Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.  It's one that investors should keep a close eye on because it could send the stock to record highs in 2025.",
      "url": "https://finnhub.io/api/news?id=2f691d66c1f43051fd84b4d8ab8e495bc31cc423ac0980c5636b516d39835474"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly and Company (LLY) Is the Best Safe Stock to Buy According to Analysts?",
    "summary": "We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best safe stocks to buy according to analysts. Market Will End 2024 Positively, Strategist Says Statistically, November and December tend […]",
    "url": "https://finnhub.io/api/news?id=25cd16a07d5136308b17e4203f7b0b2e93222460581592037e6e949ff3cc8a51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734006977,
      "headline": "Why Eli Lilly and Company (LLY) Is the Best Safe Stock to Buy According to Analysts?",
      "id": 131941686,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best safe stocks to buy according to analysts. Market Will End 2024 Positively, Strategist Says Statistically, November and December tend […]",
      "url": "https://finnhub.io/api/news?id=25cd16a07d5136308b17e4203f7b0b2e93222460581592037e6e949ff3cc8a51"
    }
  },
  {
    "ts": null,
    "headline": "Lilly s Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio in Patients with ER+, HER2- Advanced Breast Cancer",
    "summary": "INDIANAPOLIS - Eli Lilly and Company today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader , in patients with estrogen...",
    "url": "https://finnhub.io/api/news?id=4aa1f64c6ffdd2c4fc3a30d13ebee0822eed9d4ba92128b1bd771bf214c49e85",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734001897,
      "headline": "Lilly s Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio in Patients with ER+, HER2- Advanced Breast Cancer",
      "id": 131929909,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader , in patients with estrogen...",
      "url": "https://finnhub.io/api/news?id=4aa1f64c6ffdd2c4fc3a30d13ebee0822eed9d4ba92128b1bd771bf214c49e85"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Fundamental Growth Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Fundamental Growth Fund portfolio returned 1.93% for the quarter, compared with 3.19% of its benchmark, the RLG. Read more here.",
    "url": "https://finnhub.io/api/news?id=d7e61de78d3905dc0b3548cd0f93036b617f4a775fac398db91aa5606f53642d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734000960,
      "headline": "Pioneer Fundamental Growth Fund Q3 2024 Performance And Market Commentary",
      "id": 131929609,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1402582104/image_1402582104.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pioneer Fundamental Growth Fund portfolio returned 1.93% for the quarter, compared with 3.19% of its benchmark, the RLG. Read more here.",
      "url": "https://finnhub.io/api/news?id=d7e61de78d3905dc0b3548cd0f93036b617f4a775fac398db91aa5606f53642d"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Diversified International All Cap Fund Q3 2024 Commentary",
    "summary": "The Harbor Diversified International All-Cap Fund performed broadly in line with its benchmark, the MSCI All Country World Ex. US (ND) Index, during the quarter.",
    "url": "https://finnhub.io/api/news?id=80af611145c7fd4df286fcb0f1bb0c162e62aa017d826174276c90d39b310c75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733994000,
      "headline": "Harbor Diversified International All Cap Fund Q3 2024 Commentary",
      "id": 131928586,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1457855844/image_1457855844.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Harbor Diversified International All-Cap Fund performed broadly in line with its benchmark, the MSCI All Country World Ex. US (ND) Index, during the quarter.",
      "url": "https://finnhub.io/api/news?id=80af611145c7fd4df286fcb0f1bb0c162e62aa017d826174276c90d39b310c75"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: imlunestrant shows promise in breast cancer",
    "summary": "Eli Lilly announces the results of the phase 3 trial of imlunestrant in ER+ HER2- advanced breast cancer. The study showed that as a single agent, imlunestrant reduced the risk of progression or death...",
    "url": "https://finnhub.io/api/news?id=1053cee1ccb08092238b7d8b9e896bb3dbe3bdee08c26d069a51f1c9f717ee88",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733986043,
      "headline": "Eli Lilly: imlunestrant shows promise in breast cancer",
      "id": 131927137,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announces the results of the phase 3 trial of imlunestrant in ER+ HER2- advanced breast cancer. The study showed that as a single agent, imlunestrant reduced the risk of progression or death...",
      "url": "https://finnhub.io/api/news?id=1053cee1ccb08092238b7d8b9e896bb3dbe3bdee08c26d069a51f1c9f717ee88"
    }
  }
]